The DPP4 inhibitor linagliptin delays the onset of diabetes and: Preserves β-cell mass in non-obese diabetic mice

Journal of Endocrinology

Volumn 214, Issue 3, 2012, Pages 381-387

  Jelsing, Jacob ^a   Vrang, Niels ^a   van Witteloostuijn, Søren B ^a   Mark, Michael ^b   Klein, Thomas ^b  

^a Gubra ApS   (Denmark)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LINAGLIPTIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; ENDOCRINE CELL; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; STEREOLOGY;

AGE OF ONSET; ANIMALS; DIABETES MELLITUS, TYPE 1; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED NOD; PURINES; QUINAZOLINES;

EID: 84866303239     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0479     Document Type: Article

References (34)

1. Anderson MS & Bluestone JA. 2005 The NOD mouse: a model of immune dysregulation. Annual Review of Immunology 23 447-485.
2. Atkinson MA & Eisenbarth GS. 2001 Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358 221-229.
3. Bock T, Pakkenberg B & Buschard K. 2003 Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 52 1716-1722.
4. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E & Prentki M. 2004 Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47 806-815.
5. Castano L & Eisenbarth GS. 1990 Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annual Review of Immunology 8 647-679.
6. Cho JM, Jang HW, Cheon H, Jeong YT, Kim DH, Lim YM, Choi SH, Yang EK, Shin CY, Son MH et al. 2011 A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. Diabetes Research and Clinical Practice 91 72-79.
7. Deacon CF & Holst JJ. 2010 Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs. 19 133-140.
8. Delovitch TL & Singh B. 1997 The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7 727-738.
9. Dobrian AD, Ma Q, Lindsay JW, Leone KA, Ma K, Coben J, Galkina EV & Nadler JL. 2011 Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. American Journal of Physiology. Endocrinology and Metabolism 300 E410-E421.
10. Drucker DJ. 2003 Glucagon-like peptide-1 and the islet β-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144 5145-5148.
11. Drucker DJ. 2006 The biology of incretin hormones. Cell Metabolism 3 153-165.
12. Drucker DJ. 2007 Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30 1335-1343.
13. Eckhardt M, Hauel N, Himmelsbach F, Langkopf E, Nar H, Mark M, Tadayyon M, Thomas L, Guth B & Lotz R. 2008. 3,5-Dihydroimidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors. Bioorganic & Medicinal Chemistry Letters 18 3158-3162.
14. Engel M, Hoffmann T, Wagner L, Wermann M, Heiser U, Kiefersauer R, Huber R, Bode W, Demuth HU & Brandstetter H. 2003 The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. PNAS 100 5063-5068.
15. Fornari TA, Donate PB, Macedo C, Sakamoto-Hojo ET, Donadi EA & Passos GA. 2011 Development of type 1 diabetes mellitus in nonobese diabetic mice follows changes in thymocyte and peripheral T lymphocyte transcriptional activity. Clinical and Developmental Immunology. 2011 158735.
16. Fuchs H, Binder R & Greischel A. 2009 Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharmaceutics & Drug Disposition 30 229-240.
17. Hadjiyanni I, Baggio LL, Poussier P & Drucker DJ. 2008 Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149 1338-1349.
18. Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D & Dugi KA. 2009 Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes, Obesity & Metabolism 11 786-794.
19. Holst JJ. 2007 The physiology of glucagon-like peptide 1. Physiological Reviews 87 1409-1439.
20. Holz GG. 2004 Epac: a new cAMP-binding protein in support of glucagonlike peptide-1 receptor-mediated signal transduction in the pancreatic β-cell. Diabetes 53 5-13.
21. Kaneto H, Matsuoka TA, Kawashima S, Yamamoto K, Kato K, Miyatsuka T, Katakami N & Matsuhisa M. 2009 Role of MafA in pancreatic β-cells. Advanced Drug Delivery Reviews 61 489-496.
22. Kim SJ, Nian C, Doudet DJ & McIntosh CH. 2009 Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 58 641-651.
23. Kim SJ, Nian C & McIntosh CH. 2010 Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4CT-cell migration through incretin-dependent and -independent pathways. Diabetes 59 1739-1750.
24. Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, Shi H, Bonner-Weir S, Putheti P, Degauque N, Libermann TA et al. 2008 Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. PNAS 105 16242-16247.
25. Kutoh E. 2011 Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. Journal of Medical Case Reports 5 117.
26. Morimoto C & Schlossman SF. 1998 The structure and function of CD26 in the T-cell immune response. Immunological Reviews 161 55-70.
27. Reddy S, Karanam M, Krissansen G, Nitschke K, Neve J, Poole CA & Ross JM. 2000 Temporal relationship between immune cell influx and the expression of inducible nitric oxide synthase, interleukin-4 and interferongamma in pancreatic islets of NOD mice following adoptive transfer of diabetic spleen cells. Histochemical Journal 32. 195-206.
28. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M & Knudsen LB. 2002 The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. American Journal of Physiology. Endocrinology and Metabolism 283 E745-E752.
29. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM & Herold KC. 2007 Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 148 5136-5144.
30. Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, Matsuki M & Kaku K. 2011 The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 54 1098-1108.
31. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF & Egan JM. 2000 Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49 741-748.
32. Wang Q & Brubaker PL. 2002 Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45 1263-1273.
33. Xu G, Stoffers DA, Habener JF & Bonner-Weir S. 1999 Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 2270-2276.
34. Zhang J, Tokui Y, Yamagata K, Kozawa J, Sayama K, Iwahashi H, Okita K, Miuchi M, Konya H, Hamaguchi T et al. 2007 Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 50. 1900-1909.